Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato(National Cancer Center Hospital East), Byoung Chul Cho(Yonsei University), Masanobu Takahashi(Tohoku University Hospital), Morihito Okada(Hiroshima University Hospital), Chen-Yuan Lin(China Medical University Hospital), Keisho Chìn(Japanese Foundation For Cancer Research), Shigenori Kadowaki(Aichi Cancer Center), Myung‐Ju Ahn(Samsung Medical Center), Yasuo Hamamoto(Keio University), Yuichiro� Doki(Osaka University Hospital), Chueh‐Chuan Yen(National Yang Ming Chiao Tung University), Yutaro Kubota(Showa University Hospital), Sung‐Bae Kim(Ulsan College), Chih‐Hung Hsu(National Taiwan University Hospital), Eva Holtved(Odense University Hospital), Ioannis Xynos(Bristol-Myers Squibb (United States)), Mamoru Kodani(Ono Pharmaceutical (Japan)), Yuko Kitagawa(Keio University)
The Lancet Oncology
September 30, 2019
Cited by 1,225Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis